Ozempic Gastroparesis Settlement Criteria Explained

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Specific Exposure Concerns

For decades, public health communication has centered on general health and science information, providing broad guidance on wellness, disease prevention, and medical awareness. This legacy framework has served as a foundation for helping individuals understand common health risks and make informed decisions. Within this context, discussions around medication safety and side effects have typically remained at a population level, focusing on general principles rather than specific exposures. As medical science advances, the need arises to pivot from this general health perspective toward more targeted concerns, particularly regarding occupational and pharmaceutical exposure. One such area involves the growing attention to glucagon-like peptide-1 receptor agonists, including Ozempic, and their potential association with gastrointestinal complications. Specifically, reports of gastroparesis—a condition characterized by delayed gastric emptying—have prompted closer examination of exposure risks among patients using these medications. This transition from broad health education to focused exposure concern requires careful consideration of how individuals may be affected by specific pharmaceutical agents. The shift acknowledges that while general health information remains valuable, certain medical interventions warrant more detailed scrutiny regarding their potential long-term effects. Understanding the criteria for settlements related to Ozempic and gastroparesis thus emerges from this evolved perspective, moving from general awareness to specific risk assessment.

Understanding Gastroparesis and Its Link to Ozempic

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, where retention of a solid meal is measured at intervals. The condition can significantly impair quality of life and nutritional status. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular events in those with established cardiovascular disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Its mechanism involves slowing gastric emptying, which contributes to glycemic control but also underlies gastrointestinal adverse effects. Clinical trial data demonstrate that gastrointestinal adverse reactions occur more frequently with Ozempic than placebo. In a pool of placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, 32.7% of those receiving Ozempic 0.5 mg, and 36.4% of those receiving Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. Discontinuation due to gastrointestinal adverse reactions was higher in Ozempic groups: 3.1% for 0.5 mg and 3.8% for 1 mg, compared to 0.4% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred in 30.8% of the 1 mg group and 34.0% of the 2 mg group (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal adverse events, which aligns with the pharmacological action of GLP-1 receptor agonists.

Mechanistic Pathway and Evidence of Harm

The mechanistic pathway linking Ozempic to gastroparesis involves its effect on gastric motility. GLP-1 receptor agonists slow gastric emptying by inhibiting antral contractions and stimulating pyloric tone, which can lead to delayed gastric emptying. In susceptible individuals, this effect may become pathological, resulting in gastroparesis. The timeline between exposure and documented harm is variable; symptoms often emerge during dose escalation, as noted in clinical trials where the majority of nausea, vomiting, and diarrhea occurred during this period (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, chronic use may lead to persistent symptoms even after dose stabilization. Regarding the adequacy of warnings, the prescribing information for Ozempic includes gastrointestinal adverse reactions as a known risk, but does not specifically list gastroparesis as a distinct adverse event. The label mentions dyspepsia, gastroesophageal reflux disease, and gastritis, which are related but not synonymous with gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This gap in specific warning may be relevant for settlement considerations, as patients who developed gastroparesis might argue that the risk was not adequately communicated.

Settlement Criteria and Patient Considerations

Settlement-related considerations for affected patients include establishing a causal link between Ozempic use and gastroparesis, documenting the timeline of exposure and symptom onset, and demonstrating that the harm was not attributable to other causes. Patients should gather medical records showing diagnosis of gastroparesis via gastric emptying studies, prescription records for Ozempic, and documentation of symptom progression. The higher incidence of gastrointestinal adverse events in clinical trials supports a plausible association, but individual cases require careful evaluation. In summary, the evidence indicates that Ozempic is associated with a range of gastrointestinal adverse reactions, including those that could contribute to gastroparesis. The dose-dependent nature of these effects and their occurrence during dose escalation provide a mechanistic basis for harm. However, the absence of a specific gastroparesis warning in the label may be a point of contention in settlement discussions. Patients seeking settlement should focus on establishing a clear temporal relationship and excluding alternative causes. References (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166)

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the Ozempic gastroparesis settlement about?

The settlement involves claims that Ozempic (semaglutide) use may lead to gastroparesis, a condition of delayed gastric emptying. Patients who developed gastroparesis after taking Ozempic may be eligible for compensation if they meet specific criteria, including documented exposure and diagnosis.

What are the criteria for the Ozempic gastroparesis settlement?

Key criteria include: (1) documented use of Ozempic, (2) a confirmed diagnosis of gastroparesis via gastric emptying scintigraphy, (3) symptom onset during or after Ozempic use, and (4) exclusion of other causes. Medical records and prescription history are essential.

How does Ozempic cause gastroparesis?

Ozempic slows gastric emptying as part of its mechanism. In some individuals, this effect becomes pathological, leading to gastroparesis. Clinical trials show dose-dependent gastrointestinal adverse events, supporting a plausible link.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.